Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP1058 | DOI: 10.1530/endoabs.70.AEP1058

ECE2020 Audio ePoster Presentations Hot topics (including COVID-19) (110 abstracts)

Changes in metabolic control and body composition with Semaglutide sc in patients with type 2 diabetes mellitus

Enrique Redondo , Mª Carmen Serrano , Sara Leon , Mª Carmen Andreo , Luisa Sebastian , Miguel Quesada & Pablo Lopez-Ibarra

1San Cecilio University Hospital, Granada, Spain

Objectives: aGLP1 have been positioned as an effective and safe treatment in patients with Type 2 Diabetes Mellitus (DM2). The objective was to evaluate the changes metabolic and body composition at 6 months after initiation with Semaglutide weekly subcutaneous added to its basic treatment in patients with DM2.

Material and Methods: Prospective observational study. Treatment was started in 42 patients with DM2, with weekly subcutaneous Semaglutide with a 6-month follow-up. We studied clinical, biochemical, anthropometric and body composition changes. In addition, treatment adherence, side effectsand changes in dietary habit were evaluated. The body composition study was performed with Tanita TBF-300 impedancemeter. Statistical analysis was performed through the SPSS program (SPSS, inc, v 15.0).

Results: 42 patients with DM2 were recruited. Average age was 61 ± 9.7 years, 54.8% males. Baseline data: A1c 8.75 ± 1.8%, baseline blood glucose 176.55 ± 62.7 mg/dl, BMI 35.98 ± 7 kg/m2, SBP 138.7 ± 16.8 mmHg. In basal impedanciometry, the average fat mass (%), lean mass (kg) and total water (kg) was 38.1 ± 7.94%, 60.8 ± 9.9 kg and l 44.5 ± 7.2 kg respectively. 40.4% had established CVD, preferably MI. Base treatment: 64.3% metformin, 35.7% iSGLT2, insulin: 50% basal insulin analog and 11.9% rapid insulin analogues and 71.4% statins. After 6 months of treatment there were statistically significant reductions in A1C (–1.85 ± 2.09%), baseline blood glucose (–47.9 ± 74.54 mg/dl), weight (–4.92 ± 4.2 kg), BMI (–1.88 ± 1.66 kg/m2), SBP (–12.1 ± 15.5 mmHg), LDL (–17 ± 42.5 mg/dl), TG (–44.1 ± 118.37 mg/dl) and fat mass (–2.66 ± 4.37 kg). The presence of iSGLT2 in the treatment did not influence the results. Treatment adherence was 55%. 71.4% reported a greater feeling of postprandial fullness. We did not detect serious adverse effects. 50% of patients made changes in their habits diet after the introduction of semaglutide.

Conclusions: In our experience, Semaglutide treatment is very effective and sure producing very beneficial changes at metabolic level, in body composition, blood pressure, lipid profile and even dietary patterns in patients with Type 2 diabetes mellitus 6 months after the start of treatment. It is necessary collaboration strategies between patients, educators, and physicians to improve adherence to treatment.

Volume 70

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.